CA2884897C - Method of treatment or prophylaxis of infections of the eye - Google Patents
Method of treatment or prophylaxis of infections of the eye Download PDFInfo
- Publication number
- CA2884897C CA2884897C CA2884897A CA2884897A CA2884897C CA 2884897 C CA2884897 C CA 2884897C CA 2884897 A CA2884897 A CA 2884897A CA 2884897 A CA2884897 A CA 2884897A CA 2884897 C CA2884897 C CA 2884897C
- Authority
- CA
- Canada
- Prior art keywords
- integer
- dendrimer
- eye
- macromolecule
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261700714P | 2012-09-13 | 2012-09-13 | |
| US61/700,714 | 2012-09-13 | ||
| PCT/US2013/059810 WO2014043576A1 (en) | 2012-09-13 | 2013-09-13 | Method of treatment or prophylaxis of infections of the eye |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2884897A1 CA2884897A1 (en) | 2014-03-20 |
| CA2884897C true CA2884897C (en) | 2021-07-27 |
Family
ID=50278734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2884897A Active CA2884897C (en) | 2012-09-13 | 2013-09-13 | Method of treatment or prophylaxis of infections of the eye |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10149885B2 (https=) |
| EP (1) | EP2895161B1 (https=) |
| JP (2) | JP6419701B2 (https=) |
| CN (2) | CN105007910B (https=) |
| CA (1) | CA2884897C (https=) |
| DK (1) | DK2895161T3 (https=) |
| ES (1) | ES2633778T3 (https=) |
| IN (1) | IN2015DN02233A (https=) |
| WO (1) | WO2014043576A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009008006A2 (en) * | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
| RU2667118C1 (ru) * | 2017-11-15 | 2018-09-14 | Федеральное государственное бюджетное научное учреждение "Прикаспийский зональный научно-исследовательский ветеринарный институт" | Универсальное средство в виде мази для комплексного лечения глазных болезней животных и способ его получения |
| CN110664757B (zh) * | 2018-11-19 | 2022-08-02 | 成都瑞沐生物医药科技有限公司 | 纳米晶滴眼剂、其制备方法及其应用 |
| EP3930730A4 (en) * | 2020-04-15 | 2022-05-11 | Starpharma Pty Limited | PROPHYLAXIS FOR CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM623994A0 (en) | 1994-06-15 | 1994-07-07 | Biomolecular Research Institute Limited | Antiviral dendrimers |
| CN1305374A (zh) | 1998-07-14 | 2001-07-25 | 法玛西雅厄普约翰美国公司 | 治疗眼部感染的噁唑烷酮 |
| AUPP584298A0 (en) | 1998-09-14 | 1998-10-08 | Starpharma Limited | Antimicrobial and antiparasitic agents |
| AUPR412801A0 (en) * | 2001-03-30 | 2001-05-03 | Starpharma Limited | Agent for the prevention and treatment of sexually transmitted disease s - I |
| WO2005007223A2 (en) * | 2003-07-16 | 2005-01-27 | Sasha John | Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations |
| SI1755616T1 (sl) * | 2004-04-08 | 2014-04-30 | Eye Co Pty Ltd. | Zdravljenje eksudativne retinopatije z mineralkortikoidi |
| EP1937284B1 (en) | 2005-10-18 | 2015-12-02 | Starpharma Pty Limited | Microbicidal dendrimer composition delivery system |
| AU2006308511B2 (en) * | 2005-10-25 | 2013-06-13 | Starpharma Pty Limited | Macromolecular compounds having controlled stoichiometry |
| NZ583333A (en) * | 2006-05-31 | 2011-06-30 | Medihoney Pty Ltd | Medicinal Compositions Containing Honey |
| JP5484339B2 (ja) * | 2007-10-05 | 2014-05-07 | ウェイン ステート ユニバーシティー | 合成物の持続的な放出のためのデンドリマー |
| WO2010096558A1 (en) * | 2009-02-18 | 2010-08-26 | Eyeon Particle Sciences Llc | Bi-functional co-polymer use for ophthalmic and other topical and local applications |
| PL2451822T3 (pl) * | 2009-07-07 | 2014-01-31 | Adenovir Pharma Ab | Nowe związki przeciwwirusowe użyteczne do leczenia epidemicznego zapalenia spojówek i rogówki (keratoconjonctivitis) lub do zapobiegania |
| RS59598B1 (sr) | 2011-05-16 | 2020-01-31 | Starpharma Pty Ltd | Postupak lečenja ili profilakse bakterijske vaginoze |
-
2013
- 2013-09-13 CN CN201380059141.4A patent/CN105007910B/zh active Active
- 2013-09-13 WO PCT/US2013/059810 patent/WO2014043576A1/en not_active Ceased
- 2013-09-13 CA CA2884897A patent/CA2884897C/en active Active
- 2013-09-13 EP EP13837849.2A patent/EP2895161B1/en active Active
- 2013-09-13 DK DK13837849.2T patent/DK2895161T3/en active
- 2013-09-13 IN IN2233DEN2015 patent/IN2015DN02233A/en unknown
- 2013-09-13 US US14/427,970 patent/US10149885B2/en active Active
- 2013-09-13 JP JP2015532108A patent/JP6419701B2/ja active Active
- 2013-09-13 CN CN201810557127.1A patent/CN108452316B/zh active Active
- 2013-09-13 ES ES13837849.2T patent/ES2633778T3/es active Active
-
2018
- 2018-10-10 JP JP2018191652A patent/JP6766114B2/ja active Active
- 2018-11-02 US US16/179,384 patent/US11219691B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11219691B2 (en) | 2022-01-11 |
| CN105007910B (zh) | 2019-03-19 |
| US20150238557A1 (en) | 2015-08-27 |
| WO2014043576A1 (en) | 2014-03-20 |
| EP2895161B1 (en) | 2017-05-03 |
| JP2019001827A (ja) | 2019-01-10 |
| DK2895161T3 (en) | 2017-08-21 |
| US10149885B2 (en) | 2018-12-11 |
| HK1212619A1 (en) | 2016-06-17 |
| IN2015DN02233A (https=) | 2015-08-21 |
| ES2633778T3 (es) | 2017-09-25 |
| JP6419701B2 (ja) | 2018-11-07 |
| US20190070249A1 (en) | 2019-03-07 |
| JP2015528509A (ja) | 2015-09-28 |
| EP2895161A1 (en) | 2015-07-22 |
| EP2895161A4 (en) | 2016-03-23 |
| CN108452316A (zh) | 2018-08-28 |
| CA2884897A1 (en) | 2014-03-20 |
| JP6766114B2 (ja) | 2020-10-07 |
| CN108452316B (zh) | 2022-04-15 |
| CN105007910A (zh) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2448736C1 (ru) | Офтальмологическая композиция с амфотерным поверхностно-активным веществом и гиалуроновой кислотой | |
| US11219691B2 (en) | Method of treatment or prophylaxis of infections of the eye | |
| CA2253736C (en) | Antimicrobial treatment for herpes simplex virus and other infectious diseases | |
| JP6359217B2 (ja) | 新規ヨードフォア組成物および使用方法 | |
| US20130274332A1 (en) | Ophthalmic composition for contact lens | |
| HK1243354A1 (en) | Novel iodophor composition and methods of use | |
| US20250268969A1 (en) | Ophthalmic composition | |
| JP2024166367A (ja) | 眼科組成物 | |
| RU2670100C2 (ru) | Офтальмическая композиция для цвиттерионных мягких контактных линз | |
| HK1212619B (en) | Method of treatment or prophylaxis of infections of the eye | |
| TWI921304B (zh) | 以費洛西洛韋(filociclovir)治療或預防眼部感染之組合物及方法 | |
| CN100490782C (zh) | 甲磺酸帕珠沙星凝胶滴耳剂及其制备方法 | |
| HK40024783A (en) | Novel iodophor composition and methods of use | |
| CN111643448A (zh) | 一种盐酸莫西沙星眼用凝胶剂及其制备方法 | |
| TW202114690A (zh) | 以費洛西洛韋（ｆｉｌｏｃｉｃｌｏｖｉｒ）治療或預防眼部感染之組合物及方法 | |
| HK1186395A (en) | Ophthalmic composition for contact lens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180913 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240909 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240909 |